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THE AIM of this workshop was to
provide participants with the opportunity
both to discuss the technical aspects
of tumour antigen isolation and to
examine in detail the various antigen
assay procedures currently available.
The characterization of tumour anti-
gens has several important objectives
including:
(a) the isolation of "purified"
tumour products retaining their
immunological properties, so that
these may be subjected to precise
physico-chemical analysis;
(b) to provide relatively well charac-
terized antigen preparations which
may be used in in vitro assay
systems for elucidating the nature
and mechanism of action of hu-
moral factors (" blocking " fac-
tors, lymphocyte inhibitory fac-
tors) which may modify antagon-
istically cell mediated immune
responses in the autochthonous
tumour bearing individual;
(c) the development of immunodiag-
nostic procedures to provide early
cancer detection tests;
(d) to provide relatively rapid meth-
ods for monitoring tumour the-
rapy;
(e) to obtain antigenically active
material which may be suitable
for use in the immunotherapeutic
treatment of malignant disease.
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It was considered that procedures
already developed for histocompatibility
antigen isolation were applicable to the
isolation of many tumour associated
antigens, particularly those which have
been immunologically defined in experi-
mental animal model systems. For ex-
ample, solubilized tumour specific antigens
have been isolated from a number of
experimental animal tumours, including
hepatomata and sarcomata induced by
carcinogens in the rat or guinea-pig.
Furthermore, the isolation techniques
have now been applied to prepare soluble
antigens from human tumours such as
melanoma, leukaemia and carcinoma of
the colon and breast. Emphasis was,
however, placed upon the necessity for
using adequate quantities of tumour
tissue or cells for antigen extraction
since, while a few grams of tissue may be
sufficient for the preparation of relatively
crude subcellular antigenic fractions to
be used for preliminary in vivo or in vitro
tests, it may not be possible to undertake
more sophisticated studies on antigen
purification without the availability of
large amounts of tumour tissue (e.g.,
greater than 500 g). Nevertheless, from
the limited reports in the literature to
date, it is suggested that the present
progress in the isolation and characteriza-
tion ofantigens from experimental animal
tumours will make possible a more
precise evaluation of the nature of anti-
gens expressed upon human tumours.B.A.C.R. WORKSHOP
Body fluids of tumour bearing hosts
(e.g., serum, ascitic fluid, effusions) were
considered as an alternative source, other
than tumour tissues or cells, for antigen
isolation. Using animal models, free anti-
gen or antigen complexed with antibody
has been identified in serum, indicating
the possibility of isolating from body
fluids antigens which originate from the
tumour by processes such as cell mem-
brane protein turnover or cell degrada-
tion. If these findings are generally
applicable to malignant disease as pre-
liminary reports suggest, then body fluids
would certainly represent a convenient
and more readily available source of
material for the isolation of human
tumour antigens.
A major point of discussion in this
workshop was concerned with present
methods of antigen assay. Serological
tests such as membrane immunofluo-
rescence, isotopic antiglobulin tests or
serum cytotoxicity tests were considered
suitable for the further development of
assays for isolated antigens which retained
the capacity to neutralize the reactivity
of antibody in appropriate sera for
tumour cell surface expressed antigens.
The use of serological tests will also be
of major importance for resolving speci-
ficities of human tumour associated anti-
gens. Alternatively, methodological stu-
dies are progressing rapidly so that within
a short period of time detection and
quantitation of tumour antigens may be
possible on a routine basis by assay of
cell mediated immunity. When applied
to human tumours, however, both con-
ventional serological tests and assays
of cell mediated immunity require the
use of viable tumour cells obtained
directly from the cancer patient or
by establishment of tissue culture cell
lines. Because of technical difficulties
in obtaining a consistent supply of
appropriate reagents, the concensus of
opinion was that the development of
cell-free methods based upon radioim-
munoassay procedures would represent
a major achievement in the study of
human tumour associated antigens. With
respect to antigen assays in general, it
was considered that in order to promote
greater standardization of technique and
to communicate methodology more rapid-
ly, laboratories should be encouraged
both to accept workers from other insti-
tutions for short-term practical training
and to make available, in collaborative
studies, reagents such as tissue culture
cell lines, standard antisera and antigen
preparations.
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